600 patients66,869 observations120 daysLIVE

Patient P-01808

Synthetic patientNBL-101 · Day 110 · 55–64 · F · baseline S10Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S10
  2. Day 47 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 67 ME-01 recommendedMonitoring Escalation ME-01
  4. Day 68 Patient acceptedStarted ME-01 in the companion
  5. Day 71 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • GI instability+23
  • Inflammatory activity+13
  • Nutritional resilience-8
  • Toxicity-2

What helped?

  • Monitoring Escalation ME-01Day 67
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
87.9/100
stable · +2.4 vs previous 14 d
Toxicity
Blood
50.2/100
worsening · +6.4 vs previous 14 d
Sleep quality
Wearable
7.9/100
worsening · -3.1 vs previous 14 d
Energy level
Daily log
1.4/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log
7.7/10
stable · +0.3 vs previous 14 d
Steps
Wearable
6,195
worsening · -273 vs previous 14 d
Adherence
Companion
42.2 %
stable · -1.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 25 from the failing basin, 97 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 96%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 76%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 76%
Would not help
  • Keep fat low
    GI +5.7 next day on high-intake days · n 24
  • Keep histamine low
    GI +5.7 next day on high-intake days · n 23
  • Keep simple carbs low
    GI +5.2 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.7detractor · 95%
  • Histamine load
    +5.7detractor · 95%
  • Simple carbohydrates
    +5.2detractor · 95%
  • Alcohol
    +3.7detractor · 86%
  • Insoluble fibre
    +2.1no signal · 46%
  • Spicy / capsaicin
    +1.9no signal · 35%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 74
    • WearableHRV 35 ms, trending down
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 32/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 88 and rising
    • WearableSleep 5.0 h, below personal baseline
  • Autonomic recovery 45
    • WearableResting HR 74 bpm
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 32/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
37 ms
Sleep
5.4 h
Steps
6,467
Resting HR
70 bpm
Daily log: GI score 88, nutritional resilience 24, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0173644%S03ME-01improved46
P-0161941%S14GI-04worsened38
P-0144040%S12GI-04no change51
P-0172840%S14SC-12improved41
P-0173540%S1440
P-0177240%S20NP-02no change50
P-0181040%S05NP-02improved43
P-0185440%S14ME-01improved46
P-0157239%S14GI-04worsened41
P-0182239%S1437
P-0186639%S1440
P-0165538%S14GI-04no change29